MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The grant will support development of MiNK's allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT), in collaboration with the University of Wisconsin.
'This non-dilutive funding from NIAID underscores the growing recognition of iNKT cells as a unique and powerful modality in immune regulation,' said Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics. 'The work led by Dr. Gumperz and her team at the University of Wisconsin has provided important mechanistic insights into how allo-iNKT cells may not only prevent graft-versus-host disease (GvHD) but also improve the success of engraftment. Through our preclinical and clinical collaboration, we aim to address the needs of the nearly 50% of patients undergoing allogeneic stem cell transplants who are at risk for this serious and potentially life-threatening complication. This award both validates the promise of our iNKT platform and accelerates its development in a high-priority area of unmet medical need.'
GvHD is a severe immune complication that can occur after allogeneic HSCT, often leading to multi-organ damage and high mortality. iNKT cells are uniquely suited for this setting due to their natural ability to regulate immune responses, promote tissue repair, and suppress inflammatory pathways.
'Our partnership with MiNK unites their cutting-edge iNKT manufacturing with our deep expertise in transplant immunology at the University of Wisconsin-Madison,' said Jenny E. Gumperz, PhD, Professor of Medical Microbiology & Immunology, University of Wisconsin School of Medicine and Public Health. 'iNKT cells can calm the destructive allo-immune response that drives GvHD, while preserving the patient's ability to fight infection—a balance current therapies struggle to achieve. NIAID's support allows us to speed this science toward the clinic and, ultimately, give transplant patients a safer path to long-term survival.'
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells, as well as the collaboration between MiNK and Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact917-362-1370 investor@minktherapeutics.com
Media Contact781-674-4428communications@minktherapeutics.com
Gumpertz et al., Harnessing invariant natural killer T cells to control pathological inflammation. Frontiers. 2022.
Gumpertz et al., iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts. Life Sciences Alliance. 2021.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Can $10,000 in O'Reilly Automotive Stock Turn Into $61,917 by 2035?
Key Points O'Reilly Automotive has been an amazing stock performer. It's a somewhat recession-resistant business, too. But think twice before buying great stocks at any price. 10 stocks we like better than O'Reilly Automotive › So, you're interested in O'Reilly Automotive (NASDAQ: ORLY) stock. Who could blame you? It's been a terrific performer for many years, making lots of shareholders richer. You might be wondering whether it could make you richer, too. Well, it might, but there are a few issues to consider. For starters, let's review the stock's recent performance over time: Period Average Annual Gain Past 3 years 28.23% Past 5 years 26.62% Past 10 years 19.89% Past 15 years 25.53% Data source: as of July 29, 2025. I posed the question of whether you could turn $10,000 into $61,917 in a decade with O'Reilly stock because that's what would happen with average annual gains of 20%. Looking at the table above, you might think that achieving 20% average gains will be easy. That's not necessarily true, though -- because the stock's price seems a bit overheated at recent levels -- without much margin of safety. If the shares were undervalued, aiming for 20% gains would seem more reasonable. But if the shares are overvalued, then they've gotten ahead of themselves and may well pull back before advancing again. Consider these measures: O'Reilly's recent forward-looking price-to-earnings (P/E) ratio of 33.4 is well above its five-year average of 23.2. And its recent price-to-sales ratio of 5.0 is well above its five-year average of 3.7. Given all that, I won't be buying shares anytime soon. But the stock is worth adding to your watchlist in the hope of a better, lower price. It has many points in its favor. For one thing, its business is recession-resistant, should a recession rear its ugly head. When people's cars have issues, they will simply need to buy parts and supplies. And the average age of cars in America has increased recently. O'Reilly Automotive is growing well, too, posting revenue and earnings increases of 6% and 11%, respectively, in its solid second quarter. Growth investors might keep an eye on O'Reilly, but income investors should look elsewhere, as it doesn't yet pay a dividend. Should you invest $1,000 in O'Reilly Automotive right now? Before you buy stock in O'Reilly Automotive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and O'Reilly Automotive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Can $10,000 in O'Reilly Automotive Stock Turn Into $61,917 by 2035? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Mission Success for Rocket Lab's Latest Constellation Deployment Launch for iQPS
MAHIA, New Zealand, August 05, 2025--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today successfully launched its 69th Electron mission and deployed the latest satellite to orbit for Institute for Q-shu Pioneers of Space, Inc. (iQPS) - Rocket Lab's fifth dedicated mission in a multi-launch contract to build their constellation in low Earth orbit. 'The Harvest Goddess Thrives' mission lifted off from Rocket Lab Launch Complex 1 in New Zealand at 04:10 UTC on August 5th. Electron deployed a single synthetic aperture radar (SAR) imaging satellite named QPS-SAR-12 (nicknamed KUSHINADA-I for the Japanese goddess of harvest and agriculture) to a 575km circular Earth orbit. It was Rocket Lab's fourth launch this year for iQPS and fifth mission overall, making Electron the most prolific launcher of their constellation to date. Four more dedicated iQPS missions are scheduled to launch on Electron through the remainder of this year and in 2026. Rocket Lab Founder and CEO, Sir Peter Beck, says: "Every Electron launch is a demonstration of payload deployment precision for our customers – an especially critical element when scaling satellite constellations. Today's fifth and flawless deployment for iQPS once again underscores Electron's reliability and continues to prove that consistent tailored access to space is a reality on Electron for our customers." iQPS CEO, Dr. Shunsuke Onishi, says: "Building a satellite constellation requires both timely development and manufacturing, as well as highly precise launch execution. We are deeply grateful to both our team and the Rocket Lab team for their continued dedication in making this possible. As the number of satellites increases, so too does the frequency and value of the data we are able to provide. We will continue to accelerate our efforts to ensure that our satellite data can be leveraged in even more fields and applications." 'The Harvest Goddess Thrives' marks Rocket Lab's 11th Electron mission of 2025 and its 69th launch overall. Details of the next Electron launch will be shared in the coming days. Launch images: F69 | The Harvest Goddess Thrives | Flickr Launch webcast: Rocket Lab - 'The Harvest Goddess Thrives' Launch About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words "believe," "may," "will," "estimate," "potential," "continue," "anticipate," "intend," "expect," "strategy," "future," "could," "would," "project," "plan," "target," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the "SEC"), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. View source version on Contacts Rocket Lab Media Contact Murielle Bakermedia@
Yahoo
an hour ago
- Yahoo
Marex Group plc issues statement regarding NINGI Research report
LONDON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Marex Group plc ('Marex' or the 'Group'; NASDAQ: MRX), the diversified global financial services platform, provided the following response to the report that was published earlier today by NINGI Research, a short selling fund. Marex rejects this malicious report as a transparent effort to manipulate the share price to enable NINGI to profit from the short position it previously built. The report was published without any involvement by Marex. The report contains factual inaccuracies, misstatements, and misleading allegations. Marex is committed to the highest standards of integrity, managing its business in accordance with regulatory requirements in every jurisdiction where it operates. Marex reports its financial figures in accordance with international reporting standards (IFRS) and adheres to the highest standards of corporate governance. Marex will report its second quarter results on Wednesday August 13, where we look forward to the opportunity to update the market on our recent performance and respond to analyst questions. About Marex:Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to 60 exchanges. The Group provides access to the world's major commodity markets, covering a broad range of clients that include some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 40 offices worldwide, the Group has over 2,400 employees across Europe, Asia and the Americas. For more information visit Enquiries please contact: Marex:Nicola Ratchford / Adam Strachan+44 778 654 8889 / +1 914 200 2508nratchford@ astrachan@ FTI Consulting US / UK+1 919 609 9423 / +44 777 611 1222marex@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
